Cargando…

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule

Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from...

Descripción completa

Detalles Bibliográficos
Autores principales: Afra, T. P., Razmi, T Muhammed, Dogra, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362739/
https://www.ncbi.nlm.nih.gov/pubmed/30775293
http://dx.doi.org/10.4103/idoj.IDOJ_437_18